Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy.

ABSTRACT:

Background

Various cardioprotective approaches have been evaluated to prevent chemotherapy-related cardiotoxicity; however, their overall utility remains uncertain.

Objectives

To assess the effects of neurohormonal therapies in preventing cardiotoxicity in patients receiving chemotherapy.

Methods

This meta-analysis included randomized clinical trials of adult patients that underwent chemotherapy and neurohormonal therapies (beta-blockers, mineralocorticoid receptor antagonists, or ACE inhibitors/ARBs) vs. placebo with follow-up ≥4 weeks. The primary outcome was change in left ventricular ejection fraction (LVEF) from baseline to the end of trial. Other outcomes of interest were measures of LV size, strain, and diastolic function. Pooled estimates for each outcome were

SUBMITTER: Vaduganathan M 

PROVIDER: S-EPMC7571368 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature